Nevertheless, the biomarkers of neoadjuvant SBRT in combination with immunotherapy remain unknown as classical immunotherapy biomarkers such as PD-L1 and tumour mutation burden fail to dynamically reflect the changes in the TME and systemic antitumour immune response (68). Here, CD274 is linked to neoplasm.